BOLT News and Press, Bolt Biotherapeutics Inc. From 08/10/22

– BDC-1001 monotherapy and combination dose-escalation portion of the trial in HER2-expressing solid tumors on track to complete this year – New portfolio prioritization and capital allocation strategy extends expected cash runway by an additional two years – Cash b...

Gainers: Burning Rock Biotech ( BNR ) +4% . TripAdvisor  ( TRIP ) +2% . comScore ( SCOR ) +2% . Arrowhead Pharmaceuticals ( ARWR ) +2% . Bolt Biotherapeutics ( BOLT ) +2% . Losers: Swvl Holdings  ( SWVL ) ...

Gainers: Grove Collaborative ( GROV ) +80% . Faraday Future Intelligent Electric ( FFIE ) +30% . Bed Bath & Beyond ( BBBY ) +27% . Dakota Gold ( DC ) +21% . Bolt Biotherapeutics ( BOLT ) +20% . Miromatrix Medical ( MIRO...

Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...

- Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present - REDWOOD CITY, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncol...

3 Hot Penny Stocks to Watch in May 2022 Finding hot penny stocks to buy can be tricky. But if you put in the work, it can be very rewarding. One of the biggest factors to understand is researching the penny stocks on your list. This will give you a good idea of the companies you are...

Bolt Biotherapeutics press release (NASDAQ:BOLT): Q1 GAAP EPS of -$0.64 beats by $0.08. Revenue of $0.81M beats by $0.31M. Cash, cash equivalents, and marketable securities were $246.8 million as of March 31, 2022 – Cash on hand, which includes long-term marketable securities, is expec...

– BDC-1001 monotherapy and OPDIVO ® combination trials progressing toward data readouts in second half of 2022 –   C ash balance of $246.8 million expected to fund key milestones and operations into 2024 REDWOOD CITY, Calif., May 12...

REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine the targeting precision of antibodies with the power of both the innate and adaptive immun...

Shares of Bolt Biotherapeutics Inc. (NASDAQ:BOLT) traded today at $42.41, eclipsing its 52-week high. Approximately 4.3 million shares have changed hands today, as compared to an average 30-day volume of 184,000 shares. Bolt Biotherapeutics Inc. (NASDAQ:BOLT) is currently priced 7.9% abo...